mCRPC: cabazitaxel re-challenge

Alison Birtle, MBBS, MRCP, FRCR, MD, Lancashire Teaching Hospitals NHS Foundation Trust, Preston, UK, discusses cabazitaxel re-challenge therapy in metastatic castrate-resistant prostate cancer (mCRPC) patients. This interview took place at the 2020 Genitourinary Cancers Symposium, held in San Francisco, CA.

• #education
• #speaker_alison_birtle
• #event_gu_cancers_2020
• #format_interview
• #subject_genitourinary_cancer
• #subject_prostate_cancer
• #medicines_cabazitaxel
• #chemotherapy
• #field_treatment
• #medicines_docetaxel
• #medicines_abiraterone
• #medicines_pembrolizumab
• #medicines_antibodies
• #field_immuno_oncology
• #medicines_atezolizumab